Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT06506136. We help you review the study, but cannot decide medical eligibility.
Not Yet RecruitingNCT06506136
Fluoxetine for Refractory Constipation; Somatic Symptom Disorder ; Functional Constipation (FC)
This study is not yet recruiting. It is testing fluoxetine for Refractory Constipation; Somatic Symptom Disorder ; Functional Constipation (FC).
Somatic symptom disorders, Refractory Constipation, ...DrugFrom 18 Years to 70 Years
Understand this study
Who could participate?
Listed age limits: 18 years to 70 years.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: September 1, 2026
- Recruitment status
- Not Yet Recruiting
- Enrollment listed in the registry
- 194
- Sponsor
- Zhifeng Zhao, PhD
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT06506136
- Official title
- Randomized, Double-Blind, Placebo-Controlled, Single Center Trial to Evaluate the Efficacy and Safety of Fluoxetine in Patients With Refractory Constipation Exhibiting Somatic Symptom Disorder Features
Recruitment & locations
Not yet recruitingLocations not listed
Compensation and expense reimbursement have not been verified for this summary.
Registry details
Registry conditions (original wording)
Refractory Constipation; Somatic Symptom Disorder (DSM-5); Functional Constipation (FC)
Questions about this study
Who is behind this study?
The study sponsor is Zhifeng Zhao, PhD.
Does this study involve medication?
Yes. The study involves medication, including Fluoxetine and Placebo.
Who can participate?
Listed age limits: 18 years to 70 years.
Is this study still recruiting?
The registry lists this study as not yet recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingNCT06803485
Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder
This study is recruiting. It focuses on somatic symptom disorders and currently lists participation information in India.
RecruitingNCT04899687
Dextromethorphan in OCD and Related Disorders
This study is recruiting. It focuses on somatic symptom disorders and currently lists participation information in the United States.
CompletedNCT00149799
Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
This study is completed. It focuses on somatic symptom disorders and currently lists study information in the United States.